These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 31567638)

  • 1. Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease.
    Plevris N; Jenkinson PW; Arnott ID; Jones GR; Lees CW
    Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):32-37. PubMed ID: 31567638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.
    De Gregorio M; Lee T; Krishnaprasad K; Amos G; An YK; Bastian-Jordan M; Begun J; Borok N; Brown DJM; Cheung W; Connor SJ; Gerstenmaier J; Gilbert LE; Gilmore R; Gu B; Kutaiba N; Lee A; Mahy G; Srinivasan A; Thin L; Thompson AJ; Welman CJ; Yong EXZ; De Cruz P; van Langenberg D; Sparrow MP; Ding NS
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1306-1314. PubMed ID: 34389484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn's disease.
    Gu B; Venkatesh K; Williams AJ; Ng W; Corte C; Gholamrezaei A; Ghaly S; Xuan W; Paramsothy S; Connor S
    World J Gastroenterol; 2022 Jun; 28(23):2597-2608. PubMed ID: 35949350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's disease patients.
    Strik AS; Löwenberg M; Buskens CJ; B Gecse K; I Ponsioen C; Bemelman WA; D'Haens GR
    Scand J Gastroenterol; 2019 Apr; 54(4):453-458. PubMed ID: 31032686
    [No Abstract]   [Full Text] [Related]  

  • 5. Lack of anti-TNF drugs levels in fistula tissue - a reason for nonresponse in Crohn's perianal fistulating disease?
    Adegbola SO; Sarafian M; Sahnan K; Pechlivanis A; Phillips RKS; Warusavitarne J; Faiz O; Haddow J; Knowles C; Tozer P; Holmes E; Hart A
    Eur J Gastroenterol Hepatol; 2022 Jan; 34(1):18-26. PubMed ID: 33522723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment.
    de Groof EJ; Sahami S; Lucas C; Ponsioen CY; Bemelman WA; Buskens CJ
    Colorectal Dis; 2016 Jul; 18(7):667-75. PubMed ID: 26921847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease.
    Yarur AJ; Kanagala V; Stein DJ; Czul F; Quintero MA; Agrawal D; Patel A; Best K; Fox C; Idstein K; Abreu MT
    Aliment Pharmacol Ther; 2017 Apr; 45(7):933-940. PubMed ID: 28211593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial.
    Meima-van Praag EM; van Rijn KL; Wasmann KATGM; Snijder HJ; Stoker J; D'Haens GR; Gecse KB; Gerhards MF; Jansen JM; Dijkgraaf MGW; van der Bilt JDW; Mundt MW; Spinelli A; Danese S; Bemelman WA; Buskens CJ
    Lancet Gastroenterol Hepatol; 2022 Jul; 7(7):617-626. PubMed ID: 35427495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Perianal Fistulas in Crohn's Disease, Seton Versus Anti-TNF Versus Surgical Closure Following Anti-TNF [PISA]: A Randomised Controlled Trial.
    Wasmann KA; de Groof EJ; Stellingwerf ME; D'Haens GR; Ponsioen CY; Gecse KB; Dijkgraaf MGW; Gerhards MF; Jansen JM; Pronk A; van Tuyl SAC; Zimmerman DDE; Bruin KF; Spinelli A; Danese S; van der Bilt JDW; Mundt MW; Bemelman WA; Buskens CJ
    J Crohns Colitis; 2020 Sep; 14(8):1049-1056. PubMed ID: 31919501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
    Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn's Disease: A Systematic Review.
    Tandon P; Rhee GG; Schwartz D; McCurdy JD
    Dig Dis Sci; 2019 Nov; 64(11):3066-3077. PubMed ID: 31030304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
    Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approach to medical therapy in perianal Crohn's disease.
    Vasudevan A; Bruining DH; Loftus EV; Faubion W; Ehman EC; Raffals L
    World J Gastroenterol; 2021 Jul; 27(25):3693-3704. PubMed ID: 34321838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.
    Papamichael K; Cheifetz AS
    World J Gastroenterol; 2017 Sep; 23(34):6197-6200. PubMed ID: 28974885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of complex perianal fistulas with seton and infliximab in adolescents with Crohn's disease.
    Hukkinen M; Pakarinen MP; Piekkala M; Koivusalo A; Rintala R; Kolho KL
    J Crohns Colitis; 2014 Aug; 8(8):756-62. PubMed ID: 24447625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Necrosis Factor Inhibitors May Have Limited Efficacy for Complex Perianal Fistulas Without Luminal Crohn's Disease.
    McCurdy JD; Parlow S; Dawkins Y; Samji K; Rhee GG; Oliveira L; Macdonald B; Sabri E; Murthy S
    Dig Dis Sci; 2020 Jun; 65(6):1784-1789. PubMed ID: 31642006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between clinical remission of perianal fistulas in Crohn's disease and serum adalimumab concentrations: A multi-center cross-sectional study.
    Sirmai L; Pelletier AL; Gault N; Zallot C; Bouguen G; Bouchard D; Roland Nicaise P; Peyneau M; Sironneau S; Bittencourt MC; Petitcollin A; Fernandez P; Roblin X; Siproudhis L; Abramowitz L
    World J Gastroenterol; 2022 Mar; 28(9):961-972. PubMed ID: 35317057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of local adalimumab injection in patients with fistulizing perianal Crohn's disease: a pilot study.
    Tonelli F; Giudici F; Asteria CR
    Dis Colon Rectum; 2012 Aug; 55(8):870-5. PubMed ID: 22810472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease.
    Zhu M; Xu X; Feng Q; Cui Z; Wang T; Yan Y; Ran Z
    Dig Dis Sci; 2021 May; 66(5):1658-1668. PubMed ID: 32524415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination Under Anesthesia May Not Be Universally Required Prior to Anti-TNF Therapy in Perianal Crohn's Disease: A Comparative Cohort Study.
    Chan M; Fung M; Chin Koon Siw K; Khanna R; de Buck van Overstraeten A; Sabri E; McCurdy JD
    Inflamm Bowel Dis; 2023 May; 29(5):763-770. PubMed ID: 35815783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.